Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up spending, Mercer's latest survey reveals.

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

Many US employers plan to pare health benefits as weight-loss spending soars - Nation and World News | Hawaii Tribune-Herald ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...